Regorafenib for Recurrent Meningioma (MIRAGE Trial) (MIRAGE)

May 12, 2026 updated by: Istituto Oncologico Veneto IRCCS

Regorafenib for Recurrent Meningioma. A Multicenter, Randomized Phase II Study (MIRAGE Trial)

The focus of this study will be to investigate whether Regorafenib demonstrates antitumor activity against recurrent meningiomas.

Small trials and case series suggest clinical relevant activity of several VEGF inhibitors such as sunitinib, bevacizumab and valatinib reporting a 6m-PFS rate of 42-64%. Indeed, VEGF and VEGF receptors (VEGFR) are regularly overexpressed in meningiomas and can correlate with outcome.

Regorafenib inhibits angiogenic receptor tyrosine kinases (RTKs) and is highly selective for VEGFR1/2/3; moreover Regorafenib inhibits PDGFRB, FGFR1 and oncogenic intracellular signalling cascades involving c-RAF/RAF1 and BRAF highly expressed in meningiomas.

Noteworthy, Regorafenib showed antitumor activity in vitro and in vivo in a recent study; indeed, Regorafenib showed significant inhibition of meningioma cell motility and invasion and in vivo, mice with orthotopic meningioma xenografts showed a reduced volume of signal enhancement in MRI following Regorafenib therapy; this translated in a significantly increased overall survival time (p<0.05) for Regorafenib treated mice.

Moreover, Regorafenib showed good efficacy in different cancer types, such as colorectal cancer, GIST, hepatocellular carcinoma and glioblastoma (REGOMA trial) , maintainingmaintaining a good quality of life.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

104

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Italy
      • Bari, Italy
      • Bari, Italy
        • Completed
        • Ospedale San Paolo
      • Bologna, Italy
        • Recruiting
        • Ospedale Bellaria - AUSL Bologna
        • Principal Investigator:
          • Enrico Franceschi, MD
        • Contact:
      • Florence, Italy
        • Recruiting
        • Azienda Ospedaliero Universitaria Careggi
        • Contact:
        • Principal Investigator:
          • Isacco Desideri, MD
      • Genova, Italy
      • Livorno, Italy
      • Milan, Italy
        • Recruiting
        • IRCCS Ospedale San Raffaele
        • Contact:
        • Principal Investigator:
          • Nicole Liscia, MD
      • Milan, Italy
        • Recruiting
        • Fondazione IRCCS Istituto Neurologico Carlo Besta
        • Contact:
        • Principal Investigator:
          • Paola Gaviani, MD
      • Naples, Italy
        • Recruiting
        • Ospedale del Mare
        • Principal Investigator:
          • Bruno Daniele, MD
        • Contact:
      • Padova, Italy, 35128
      • Roma, Italy
        • Recruiting
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
        • Contact:
        • Principal Investigator:
          • Silvia Chiesa, MD
      • Roma, Italy
        • Not yet recruiting
        • Policlinico Umberto I - Università Sapienza Roma
        • Contact:
        • Principal Investigator:
          • Giuseppe Minniti, MD
      • Roma, Italy
        • Recruiting
        • IRCCS Istituto Tumori Regina Elena
        • Contact:
        • Principal Investigator:
          • Veronica Villani, MD
      • Torino, Italy
        • Recruiting
        • A.O.U. Città della Salute e Della Scienza di Torino
        • Contact:
        • Principal Investigator:
          • Roberta Rudà, MD
    • Forlì-Cesena
      • Meldola, Forlì-Cesena, Italy
        • Recruiting
        • IRST Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
        • Contact:
        • Principal Investigator:
          • Lorena Gurrieri, MD
    • Italia/Messina
      • Messina, Italia/Messina, Italy, 98124
    • Milano
      • Rozzano, Milano, Italy
        • Recruiting
        • Humanitas Cancer Center
        • Contact:
        • Principal Investigator:
          • Matteo Simonelli, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted
  • Patients capable of taking oral medication
  • Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
  • Histological diagnosis of meningioma according to the WHO 2021 classification
  • Radiologically documented progression of any existing tumor with an estimated planar growth >25% (bidirectional) in the last 12 months or appearance of new lesions
  • Ineligible for further surgery and/or radiotherapy
  • at least 1 Measurable lesion (minimum 10 x 10mm) on baseline MRI
  • Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1 (or KPS ³70)
  • Male or female ≥ 18 years of age
  • Subjects must have life expectancy of at least 6 months
  • Paraffin-embedded tumor tissue available (mandatory)
  • Dosage of dexamethasone or equivalent steroid within 7 days prior the randomization ≤4mg/die
  • Stable or decreasing dosage of steroids for 7 days prior to the randomization.
  • Adequate cardiac function and adequate liver, renal and hematological function
  • Subject must have the following laboratory values at screening within 14 days before starting Regorafenib:
  • Absolute neutrophil count (ANC) ≥ 1.5 x 109/L without growth factor support for 7 days (14 days if subject received pegfilgrastim).
  • Hemoglobin (Hgb) ≥10 g/dL
  • Platelet count (plt) ≥100x 109/L
  • Serum potassium concentration within normal range, or correctable with supplements
  • Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) and serum glutamate pyruvic transaminase (SGPT)/alanine aminotransferase (ALT) ≤ 3.0 x Upper Limit of Normal (ULN).
  • Serum total bilirubin ≤ 1.5 x ULN
  • Serum creatinine ≤ 1.5 x ULN or measured glomerular filtration rate (GFR) ≥ 50 mL/min/1.73 m2 using an exogenous filtration marker such as iohexol, inulin, 51Cr EDTA or 1125 iothalamate, or creatinine clearance of ≥ 50 mL/min using Cockroft-Gault equation.
  • Serum albumin > 3.5 g/dL
  • PT (or INR) and APTT within normal range
  • For women who are not postmenopausal (i.e., < 2 years after last menstruation) or surgically sterile (absence of ovaries and/or uterus) and who are sexually active: agreement to use an adequate method of contraception (oral contraceptives, intrauterine contraceptive device, or barrier method of contraception in conjunction with spermicidal jelly) during the Treatment period and for at least 6 months after the last dose of study drug.
  • For male patients who are partners of premenopausal women: agreement to use a barrier method of contraception during the Treatment period and for at least 6 months after the last dose of study drug.
  • Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to participate.
  • 19. Patients with measurable, progressive meningioma who received radiation therapy are potentially eligible but need to show evidence of progression at least 24 weeks from completion of radiation therapy.
  • 20. Possible prior use of bevacizumab in the treatment of radionecrosis (3-24 months after radiosurgery or radiotherapy; 5mg/kg q14w, 4-6 cycles)

Exclusion Criteria:

  • Prior antineoplastic therapy for meningioma
  • Subject incapacitated to understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted
  • Are taking strong cytochrome P (CYP) CYP3A4 inhibitors (eg, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifampin, St. John's Wort)
  • Are taking strong UGT1A9 inhibitors (e.g. mefenamic acid, diflunisal and niflumic acid)
  • Receiving additional, concurrent, active therapy for Meningioma outside of the trial.
  • Disease outside the brain (ie. spinal cord or bone or metastasis to a distant organ)
  • Candidate for urgent palliative intervention for primary disease (e.g., impending herniation) as judged by the Investigator
  • History of allergy or hypersensitivity to any of the study treatments or any of their excipients.
  • In the presence of therapeutic intent to anticoagulate the patient:,INR or PT and aPTT not within therapeutic limits (according to the medical standard in the institution)
  • Unable or unwilling to undergo brain MRI scans with intravenous (IV) gadolinium
  • History of another malignancy in the previous 3 years, with a disease-free interval of< 3 years. Patients with prior history of in situ cancer or basal or squamous cell skin cancer are eligible.
  • Serious, non-healing wound, ulcer, bone fracture, or abscess.
  • Any cerebrovascular accident (including transient ischemic attacks) within the last 6 months prior to initiation of study treatment.
  • Have an ongoing infection with severity of Grade 2 or above (CTCAE 5.0)
  • Any hemorrhage or bleeding event that is ≥ Grade 3 based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE), Grade 2 intracranial hemorrhage, or persistent thrombotic/embolic event within 4 weeks prior to the start of study medication.
  • Uncontrolled or severe cardiac disease (e.g., history of unstable angina, myocardial infarction, coronary stenting, or bypass surgery within the last 6 months prior to initiation of study treatment), symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia (including atrial flutter/fibrillation), requirement for inotropic support or use of devices for cardiac conditions (e.g.,pacemakers/defibrillators), or hypertension (participants with systolic blood pressure[BP] of > 160 mmHg or diastolic BP of > 100 mmHg despite optimal medical management are to be excluded).
  • History of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis, or symptomatic pleural effusion.
  • Active, known, or suspected auto-immune disease, including systemic lupus erythematosus, Hashimotos thyroiditis, scleroderma, polyarteritis nodosa, or auto-immune hepatitis.
  • Known history of hepatitis B, human immunodeficiency virus (HIV), or active hepatitis C infection requiring treatment with antiviral therapy. Note: HIV testing is not required in the absence of clinical suspicion.
  • History of bleeding diathesis (irrespective of severity).
  • Uncontrolled intercurrent illness including (e.g., symptomatic ascites), but not limited to ongoing or active infection.
  • Persistent ≥ Grade 3 Lipase (> 2.0 - 5.0 x upper limit of normal [ULN] with signs or symptoms; > 5.0 x ULN and asymptomatic).
  • Persistent proteinuria > 3.5 g/24 hours measured by urine protein creatinine ratio from a random urine sample (≥ Grade 3, CTCAE 5.0)
  • Have any malabsorbition condition
  • Any condition that could make the subject noncompliant with the study procedures and/or study requirements, as judged by the Investigator (for example: cognitive impairment, psychiatric illness, etc).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Arm A (interventional arm)
REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity
Drug: Regorafenib 40 MG Oral Tablet
REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity
Active Comparator: Arm B (control arm)
Local Standard of Care until disease progression or unacceptable toxicity
Drug: Local Standard of Care
In this setting there are not drugs with indication. Every site will treat patients as per their experience.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Progression free survival (PFS)
Time Frame: Up to 36 months
The progression free survival (PFS) will be determined as the time from the date of enrolment to the date of disease progression determined using RANO criteria or to the date of death, whichever occurs first.
Up to 36 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall survival (OS)
Time Frame: Up to 30 months
The overall survival (OS) will be determined as the time from the date of enrolment to the date of death from any cause.
Up to 30 months
Objective response rate (ORR)
Time Frame: Up to 30 months
The objective response rate (ORR) will be defined as the percentage of patients with complete response (CR) and partial response (PR) determined using modified Macdonald criteria.
Up to 30 months
Patient Reported Outcomes (PROs)
Time Frame: Up to 30 months
Quality of life will be assessed by EORTC QLQ-C30 questionnaire.
Up to 30 months
Patient Reported Outcomes (PROs)
Time Frame: Up to 30 months
Quality of life will be assessed by the QLQBN20 questionnaire.
Up to 30 months
Toxicity during treatment
Time Frame: Up to 30 months
Toxicity during the treatment will be recorded and graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v.5.
Up to 30 months
Disease control rate (DCR)
Time Frame: Up to 30 months
The disease control rate (DCR) will be defined as the percentage of patients with complete response (CR), partial response (PR) and stable disease (SD) determined using modified Macdonald criteria.
Up to 30 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Istituto Oncologico Veneto IRCCS

Collaborators

Bayer

Investigators

  • Principal Investigator: Giuseppe Lombardi, MD, Istituto Oncologico Veneto IOV IRCCS

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 23, 2024

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

March 1, 2027

Study Registration Dates

First Submitted

February 7, 2024

First Submitted That Met QC Criteria

February 16, 2024

First Posted (Actual)

February 23, 2024

Study Record Updates

Last Update Posted (Actual)

May 13, 2026

Last Update Submitted That Met QC Criteria

May 12, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IOV-BT-1-2023 MIRAGE

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Meningioma, Malignant

Clinical Trials on Regorafenib 40 MG Oral Tablet

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe